| Biomarker ID | 852 |
| PMID | 22298030 |
| Year | 2012 |
| Biomarker | miR-25 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome |
| Experiment | prostate cancer Vs benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Training set: 25 patients with prostate cancer, 17 with Benign prostatic hyperplasia. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Training: p<0.0001; Not significant in validation set |
| Method Used | Training Set: Microarrays, Validation set; qRT-PCR |
| Clinical | No |
| Remarks | Not significant in Validation set |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | miR-25 |